Piotr J. Wysocki, Professor of Medicine and Head of Department of Oncology at Jagiellonian University Hospital in Poland, shared on LinkedIn:
“The final results of the POUT trial have been published online in J Clin Oncol by Biscombe K et al. In this seminal study, 261 muscle-invasive or node-positive disease upper tract urothelial cancer (UTUC) patients were randomized to platinum-based adjuvant chemotherapy or surveillance.
The treatment was initiated within 90 days after surgery. In the interventional arm, patients received 4 cycles of adjuvant gemcitabine+cisplatin combination or, in the case of eGFR<30-49 ml/min – gemcitabine+carboplatin combination.
After a median follow-up of 65 months, the 5-year DFS was significantly improved in the adjuvant chemotherapy arm compared to surveillance (62% v. 45% – HR for DFS = 0.55; 95%CI 0.38-0,80). The 5-year OS was 66% v. 57% – HR for OS = 0.68; 95%CI 0.46-1.00, p=0.049)
The OS was not the primary endpoint but the results of this strongly support the use of adjuvant chemotherapy in UTUC patients, especially if cisplatin+gemcitabine combination is used. In a subgroup analysis of overall survival in the cisplatin+gemcitabine subgroup, the HR for OS was 0.57 (95%CI 0.33-0.97), whereas for carboplatine+gemcitabine combination, the HR for OS was 0.87 (95%CI 0.50-1.53).”
Source: Piotr J. Wysocki/LinkedIn